MA37866A1 - Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur - Google Patents

Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Info

Publication number
MA37866A1
MA37866A1 MA37866A MA37866A MA37866A1 MA 37866 A1 MA37866 A1 MA 37866A1 MA 37866 A MA37866 A MA 37866A MA 37866 A MA37866 A MA 37866A MA 37866 A1 MA37866 A1 MA 37866A1
Authority
MA
Morocco
Prior art keywords
indazole
pain
treatment
diaza
aza
Prior art date
Application number
MA37866A
Other languages
Arabic (ar)
English (en)
Other versions
MA37866B1 (fr
Inventor
Pierre Sokoloff
Frédéric Cachoux
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA37866A1 publication Critical patent/MA37866A1/fr
Publication of MA37866B1 publication Critical patent/MA37866B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule (i) suivante ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, un tautomère de celui-ci ou un stéréo-isomère ou un mélange de stéréo-isomères de celui-ci dans des proportions quelconques, tel qu'un mélange d'énantiomères, notamment un mélange racémique, destiné à être utilisé dans le traitement de la douleur.
MA37866A 2012-07-27 2015-02-23 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur MA37866B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (fr) 2012-07-27 2012-07-27 Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
PCT/EP2013/065907 WO2014016433A1 (fr) 2012-07-27 2013-07-29 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Publications (2)

Publication Number Publication Date
MA37866A1 true MA37866A1 (fr) 2016-05-31
MA37866B1 MA37866B1 (fr) 2016-12-30

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37866A MA37866B1 (fr) 2012-07-27 2015-02-23 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Country Status (28)

Country Link
US (1) US9381195B2 (fr)
EP (2) EP2689778A1 (fr)
JP (2) JP6456823B2 (fr)
KR (1) KR102120505B1 (fr)
CN (1) CN104684554B (fr)
AU (1) AU2013294920B2 (fr)
BR (1) BR112015001502B1 (fr)
CA (1) CA2879595C (fr)
CY (1) CY1118478T1 (fr)
DK (1) DK2877177T3 (fr)
ES (1) ES2612349T3 (fr)
HR (1) HRP20170104T1 (fr)
HU (1) HUE032919T2 (fr)
IL (1) IL236917A (fr)
LT (1) LT2877177T (fr)
MA (1) MA37866B1 (fr)
MX (1) MX363605B (fr)
MY (1) MY183398A (fr)
NZ (1) NZ705253A (fr)
PL (1) PL2877177T3 (fr)
PT (1) PT2877177T (fr)
RS (1) RS55646B1 (fr)
RU (1) RU2640046C2 (fr)
SI (1) SI2877177T1 (fr)
TN (1) TN2015000034A1 (fr)
UA (1) UA116107C2 (fr)
WO (1) WO2014016433A1 (fr)
ZA (1) ZA201501209B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ME03376B (fr) 2010-05-20 2020-01-20 Array Biopharma Inc Composés macrocycliques comme inhibiteurs de la kinase trk
EP2689778A1 (fr) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
WO2015143652A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
KR20170095814A (ko) 2014-10-06 2017-08-23 플랫틀리 디스커버리 랩, 엘엘씨 트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
EP3233840B1 (fr) 2014-12-16 2018-11-21 Eudendron S.r.l. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
EP3368039A1 (fr) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (fr) 2016-05-18 2020-11-25 Loxo Oncology Inc. Préparation de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (fr) * 2016-10-31 2018-05-03 塩野義製薬株式会社 Hétérocycle fusionné ayant une activité inhibitrice de trka et dérivé carbocycle fusionné
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US12583852B2 (en) 2018-05-02 2026-03-24 Jw Pharmaceutical Corporation Heterocycle derivative
KR102129114B1 (ko) 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (fr) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- et pyrido-pyrazoles en tant qu`inhibiteurs de protéine kinase
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
AU2024275348A1 (en) * 2023-05-24 2025-12-11 Changchun Genescience Pharmaceutical Co., Ltd. Fgfr2/3 selective inhibitor, pharmaceutical composition and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
EP1215208B1 (fr) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. Dérivées de 4-aminothiazole, leur préparation et leur utilisation comme inhibiteurs des kinases cycline-depenents
EP1292586B1 (fr) 2000-06-22 2004-08-04 Pfizer Limited Procede de preparation de pyrazolopyrimidinones
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
MX2009006401A (es) * 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008112695A2 (fr) * 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
US8354399B2 (en) * 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (fr) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur

Also Published As

Publication number Publication date
KR20150038295A (ko) 2015-04-08
MY183398A (en) 2021-02-18
MA37866B1 (fr) 2016-12-30
SI2877177T1 (sl) 2017-02-28
CN104684554A (zh) 2015-06-03
HK1207302A1 (en) 2016-01-29
EP2689778A1 (fr) 2014-01-29
EP2877177B1 (fr) 2016-10-26
JP6456823B2 (ja) 2019-01-23
PL2877177T3 (pl) 2017-04-28
UA116107C2 (uk) 2018-02-12
BR112015001502B1 (pt) 2023-03-07
RU2015106434A (ru) 2016-09-20
JP2015522650A (ja) 2015-08-06
TN2015000034A1 (en) 2016-06-29
CY1118478T1 (el) 2017-07-12
CA2879595A1 (fr) 2014-01-30
US20150190394A1 (en) 2015-07-09
IL236917A (en) 2016-11-30
RS55646B1 (sr) 2017-06-30
JP2019031542A (ja) 2019-02-28
AU2013294920B2 (en) 2017-08-24
BR112015001502A2 (pt) 2017-07-04
ZA201501209B (en) 2016-03-30
US9381195B2 (en) 2016-07-05
CN104684554B (zh) 2017-05-10
HUE032919T2 (hu) 2017-11-28
JP6732855B2 (ja) 2020-07-29
HRP20170104T1 (hr) 2017-03-24
ES2612349T3 (es) 2017-05-16
PT2877177T (pt) 2017-02-06
MX2015001009A (es) 2015-06-04
WO2014016433A1 (fr) 2014-01-30
LT2877177T (lt) 2017-01-25
RU2640046C2 (ru) 2017-12-26
DK2877177T3 (en) 2017-02-06
AU2013294920A1 (en) 2015-03-12
EP2877177A1 (fr) 2015-06-03
KR102120505B1 (ko) 2020-06-08
MX363605B (es) 2019-03-26
NZ705253A (en) 2017-05-26
CA2879595C (fr) 2020-07-28

Similar Documents

Publication Publication Date Title
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
EP3412668A3 (fr) Un inhibiteur de la phosphatidylinositol-3-kinase gamma
TN2014000112A1 (en) Ep1 receptor ligands
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX364400B (es) Compuestos de tetraciclina.
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
CA2922375C (fr) Formes de sels d'alpha-tea: compositions et utilisations therapeutiques
EA201490573A1 (ru) Соединение бензотиазолона
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA201690908A1 (ru) Пиразолопиримидиновые соединения
PH12015502703A1 (en) Pharmaceutical compositions